Only one trial of a genetically modified T cell receptor fusion construct required 2+/3+ MSLN expression in ≥ 50% viable tumour cells by IHC as its sole inclusion criterion relating to MSLN expression.19 The gene discussed is MSLN; the disease is neoplasm.